Testing several treatments, including efgartigimod and empasiprubart, in adults with myasthenia gravis
Tests the safety and effects of different treatments in adults with myasthenia gravis.
Plain-language title generated from the registry record
Registry title: ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Key facts
- Where
- Barcelona and Málaga, SpainSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with myasthenia gravis. It tests how safe and how effective different drugs are.
- Age
- 18 years or older, and at least the local legal age of consent for clinical studies
- Sex
- All sexes can join
- Disease stage
- Diagnosed with myasthenia gravis with consistent clinical features, in the investigator's judgment. People in MGFA Class V cannot join.
- Earlier treatment
- If you take myasthenia gravis medicines (nonsteroidal immunosuppressive drugs, corticosteroids or acetylcholinesterase inhibitors), the dose must have been stable before screening.
Main reasons for not taking part
- Another known autoimmune disease or medical condition that would interfere with assessing myasthenia gravis symptoms or put you at undue risk
- MGFA (Myasthenia Gravis Foundation of America) Class V
Read by machine on 13 November 2026.
Where in Spain
- Hospital de la Santa Creu i Sant PauBarcelona, SpainContact: Elena Cortes Vicente, MDTaking people
- Hospital Regional Universitario de Malaga - Hospital GeneralMálaga, SpainContact: Guillermina García Martín, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- argenx
- Trial code
- NCT07294170
- Record updated
- 26 October 2026
- Original description
ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.Read full original descriptionShow less
A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.
Inclusion: Is at least 18 years of age and the local legal age of consent for clinical studies; Has been diagnosed with MG with consistent clinical features per the investigator's clinical judgment; If receiving MG therapy, including nonsteroidal immunosuppressive drugs (NSIDs), corticosteroids, or acetylcholinesterase (AChE) inhibitors either in combination or alone, the participant should receive a stable dosage before master protocol screening.
Exclusion: Known autoimmune disease or any medical condition other than the indication under study that would interfere with an accurate assessment of clinical symptoms of MG or puts the participant at undue risk; Is MGFA (Myasthenia Gravis Foundation of America) Class V.